Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Open-label, Multicenter, Randomized, Dose Escalation Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

NCT06695026 is registered in ClinicalTrials.gov with Rznomics, Inc. as lead sponsor.

NCT NCT06695026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06695026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Open-label, Multicenter, Randomized, Dose Escalation Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Lead sponsor
Rznomics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 18, 2024
Completion date
October 31, 2027
Enrollment
45 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)